# Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Study · id `cardio:ct-nct06603870` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06603870](<https://clinicaltrials.gov/study/NCT06603870>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06603870

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT06603870. Allocation not applicable; no masking; primary purpose treatment. Start 2024-12-19 (actual); primary completion 2029-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT06603870, source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)
- Started: 2024-12-19 (actual) (ClinicalTrials.gov record NCT06603870, source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)
- Primary completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT06603870, source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)
- Completion: 2029-10 (anticipated) (ClinicalTrials.gov record NCT06603870, source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT06603870, source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06603870-2026-09-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
- Acronym: STREAM-Line
- Condition: Venous Thromboembolism
- Condition: Cancer
- Condition: Upper Extremity Deep Vein Thrombosis
- Condition: Catheter-Related Infections
- Intervention (Drug): Anticoagulation Therapy
- Lead sponsor: Ottawa Hospital Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry lists this organization as the lead sponsor: Ottawa Hospital Research Institute (`cardio:org-ottawa-hospital-research-institute`)

## Provenance

Content hash: df4cd39e46829fb9e42c06ef7ce286dc29d00759409f9a6d058275d3d54d2abd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
